Mitchell S von Itzstein
Overview
Explore the profile of Mitchell S von Itzstein including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
43
Citations
256
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Gerber D, Mayer M, Gagan J, von Itzstein M
JTO Clin Res Rep
. 2022 Mar;
3(3):100291.
PMID: 35295963
Introduction: L747P mutations occur rarely, with limited preclinical research and case reports suggesting resistance to osimertinib. Main Concerns Important Clinical Findings Primary Diagnoses Interventions Outcomes: An 84-year-old white male with...
22.
von Itzstein M, Gonugunta A, Sheffield T, Homsi J, Dowell J, Koh A, et al.
Cancers (Basel)
. 2022 Mar;
14(5).
PMID: 35267634
Antibiotic administration is associated with worse clinical outcomes and changes to the gut microbiome in cancer patients receiving immune checkpoint inhibitors (ICI). However, the effects of antibiotics on systemic immune...
23.
von Itzstein M, Gonugunta A, Wang Y, Sheffield T, Lu R, Ali S, et al.
Cancer Immunol Immunother
. 2022 Jan;
71(9):2169-2181.
PMID: 35072744
Background: Thyroid dysfunction is among the most common autoimmune diseases and immune checkpoint inhibitor (ICI)-induced immune-related adverse events (irAE). We determined the association between longitudinal thyroid function and clinical outcomes...
24.
Hsiehchen D, Naqash A, Espinoza M, von Itzstein M, Cortellini A, Ricciuti B, et al.
Oncoimmunology
. 2022 Jan;
11(1):2017162.
PMID: 35003896
The timing of immune-related adverse events (irAE) associated with immune checkpoint inhibitors (ICI) is highly variable. Although the development of irAE has been associated with ICI clinical benefit, how irAE...
25.
Gonugunta A, von Itzstein M, Mu-Mosley H, Fattah F, Farrar J, Mobely A, et al.
J Immunother Cancer
. 2021 Dec;
9(12).
PMID: 34880115
Immune-related adverse events (irAE) may affect almost any organ system and occur at any point during treatment with immune checkpoint inhibitors (ICI). We present a patient with advanced lung cancer...
26.
von Itzstein M, Drapkin B, Minna J
Elife
. 2021 Aug;
10.
PMID: 34346867
Changes in MAPK signaling allow lung cancer cells to transition between lineages that respond differently to treatment.
27.
von Itzstein M, Gerber D, Minna J
Cancer Res
. 2021 Jul;
81(13):3441-3443.
PMID: 34252039
In this issue, the study by Dagnino and colleagues represents an important addition to the maturing field of blood-based biomarkers for lung cancer screening. Their comprehensive approach to analyzing circulating...
28.
von Itzstein M, Hullings M, Mayo H, Beg M, Williams E, Gerber D
JAMA Oncol
. 2021 Jul;
7(10):1559-1566.
PMID: 34236403
Importance: As cancer treatment has become more individualized, oncologic clinical trials have become more complex. Increasingly numerous and stringent eligibility criteria frequently include tumor molecular or genomic characteristics that may...
29.
Ahmed M, von Itzstein M, Sheffield T, Khan S, Fattah F, Park J, et al.
J Immunother Cancer
. 2021 Jun;
9(6).
PMID: 34127546
Background: Increased body mass index (BMI) has been associated with improved response to immune checkpoint inhibitors (ICIs) in multiple cancer types. We evaluated associations between BMI, ICI dosing strategy, and...
30.
von Itzstein M, Smith M, Railey E, White C, Dieterich J, Garrett-Mayer L, et al.
JCO Oncol Pract
. 2021 May;
17(7):e999-e1011.
PMID: 33970688
Purpose: Advances in genomic techniques have led to increased use of next-generation sequencing (NGS). We evaluated the extent to which these tests guide treatment decisions. Methods: We developed and distributed...